Myriad Genetics' Q3 Revenues up 13 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market on Tuesday that sales of BRACAnalysis products drove its total revenues up 13 percent year over year in its fiscal third quarter.

Revenues for Myriad during the three months ended March 31 totaled $102.4 million, compared to $90.8 million a year ago, exceeding consensus Wall Street forecasts for $98.2 million in revenue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.